GLP-1 receptor agonists, such as semaglutide and tirzepatide, are a class of medications initially developed to help manage type 2 diabetes
Together with IL-3, IGF-I stimulates differentiation and proliferation of myeloid cells and has been shown to regulate lymphopoiesis by stimulating proliferation and differentiation of T and B cells in lymphoid organs (Heemskerk et al.)
In addition, the GLP-1R-mediated AMPK phosphorylation pathway can also optimize the muscle fiber types, improve glycogen storage and glucose uptake, further synergistically enhancing the athletic performance of skeletal muscle [19]
Comparing Delivery Methods: Evidence for Efficacy and Consistency Injectable GLP-1 medications (semaglutide, tirzepatide) show robust clinical evidence with weight loss ranges of 1022% and HbA1c reductions of 12 percentage points in published trials
Endocrinology 156 (7), 24172428